The success of corneal crosslinking (CXL) for ectatic disease requires oxygen within the tissue, and this dependency likely explains the limited efficiency of high-intensity (rapid) and transepithelial treatment protocols, said Farhad Hafezi, MD, PhD
Scientific article describing the first use of cross-linking to treat TMD
ELZA members define the new term for cross-linking for corneal infection
Farhad Hafezi: invited speaker.
Farhad Hafezi receives the 2014 IIRSI Gold Medal from IIRSI President Amar Agarwal, for his efforts to introduce corneal cross-linking into clinical ophthalmology.
Farhad Hafezi: invited speaker (see the program here) and recipient of the 2014 IIRSI Gold Medal.
Farhad Hafezi: invited speaker in Birmingham, England
Farhad Hafezi: invited speaker in Lodz, Poland
Laboratory study showing that CXL at high intensities is less efficient biomechanically
Review by ELZA member Farhad Hafezi (article in French).